BioNTech (NASDAQ:BNTX) Now Covered by Truist Financial

Investment analysts at Truist Financial began coverage on shares of BioNTech (NASDAQ:BNTX) in a note issued to investors on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $172.00 price target on the stock. Truist Financial’s price target would indicate a potential upside of 40.81% from the stock’s current price.

Several other research firms have also commented on BNTX. Canaccord Genuity Group lifted their price target on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Bank of America lifted their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Berenberg Bank started coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Finally, Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Stock Down 3.7 %

Shares of BNTX opened at $122.15 on Friday. The business’s 50 day simple moving average is $114.07 and its 200-day simple moving average is $103.06. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market capitalization of $29.28 billion, a price-to-earnings ratio of -58.17 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the prior year, the firm earned $0.73 earnings per share. BioNTech’s revenue was up 38.9% on a year-over-year basis. As a group, equities analysts expect that BioNTech will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Large investors have recently modified their holdings of the company. Baillie Gifford & Co. increased its holdings in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the period. FMR LLC grew its position in shares of BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares in the last quarter. Deerfield Management Company L.P. Series C increased its stake in shares of BioNTech by 4.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after buying an additional 24,426 shares during the period. Fred Alger Management LLC bought a new stake in shares of BioNTech in the third quarter valued at about $59,485,000. Finally, DekaBank Deutsche Girozentrale lifted its stake in BioNTech by 12.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock worth $56,886,000 after acquiring an additional 53,800 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.